Hvsen Biotechnology Co., Ltd.

SZSE:300871 Stock Report

Market Cap: CN¥1.9b

Hvsen Biotechnology Past Earnings Performance

Past criteria checks 0/6

Hvsen Biotechnology's earnings have been declining at an average annual rate of -50.4%, while the Pharmaceuticals industry saw earnings growing at 9.1% annually. Revenues have been growing at an average rate of 9.8% per year.

Key information

-50.4%

Earnings growth rate

-53.6%

EPS growth rate

Pharmaceuticals Industry Growth10.9%
Revenue growth rate9.8%
Return on equity-3.2%
Net Margin-4.1%
Last Earnings Update30 Sep 2024

Recent past performance updates

Recent updates

Hvsen Biotechnology Co., Ltd. (SZSE:300871) Stock Catapults 26% Though Its Price And Business Still Lag The Industry

Nov 14
Hvsen Biotechnology Co., Ltd. (SZSE:300871) Stock Catapults 26% Though Its Price And Business Still Lag The Industry

Hvsen Biotechnology Co., Ltd.'s (SZSE:300871) Share Price Boosted 25% But Its Business Prospects Need A Lift Too

Sep 30
Hvsen Biotechnology Co., Ltd.'s (SZSE:300871) Share Price Boosted 25% But Its Business Prospects Need A Lift Too

Hvsen Biotechnology Co., Ltd. (SZSE:300871) Shares Could Be 21% Below Their Intrinsic Value Estimate

Aug 21
Hvsen Biotechnology Co., Ltd. (SZSE:300871) Shares Could Be 21% Below Their Intrinsic Value Estimate

Take Care Before Jumping Onto Hvsen Biotechnology Co., Ltd. (SZSE:300871) Even Though It's 27% Cheaper

Jun 05
Take Care Before Jumping Onto Hvsen Biotechnology Co., Ltd. (SZSE:300871) Even Though It's 27% Cheaper

Hvsen Biotechnology Co., Ltd. (SZSE:300871) Stocks Shoot Up 37% But Its P/E Still Looks Reasonable

Mar 29
Hvsen Biotechnology Co., Ltd. (SZSE:300871) Stocks Shoot Up 37% But Its P/E Still Looks Reasonable

Revenue & Expenses Breakdown

How Hvsen Biotechnology makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

SZSE:300871 Revenue, expenses and earnings (CNY Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 241,121-4615652
30 Jun 241,007-5115552
31 Mar 24996-1415550
31 Dec 231,0201715545
30 Sep 231,0434112945
30 Jun 231,0756212242
31 Mar 231,0486611540
01 Jan 231,0235311340
30 Sep 22922408445
30 Jun 22857388049
31 Mar 22888718351
01 Jan 229961338147
30 Sep 211,02717310441
30 Jun 211,02619910534
31 Mar 219561889931
31 Dec 207771509128
30 Sep 206551307922
31 Dec 19427696421
31 Dec 18422717920
31 Dec 17400887818
31 Dec 16258496313

Quality Earnings: 300871 is currently unprofitable.

Growing Profit Margin: 300871 is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: 300871 is unprofitable, and losses have increased over the past 5 years at a rate of 50.4% per year.

Accelerating Growth: Unable to compare 300871's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: 300871 is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (-2.5%).


Return on Equity

High ROE: 300871 has a negative Return on Equity (-3.21%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Discover strong past performing companies